Prof. Dr. SERKAN AKIN

Yayın Ağı

Makaleler 55

1. Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey

Dişli A. K., Durukan B. M., Aşık E., NURANSOY CENGİZ A., Emin G., Yıldırım H. Ç., et al.

Medicina (Lithuania) , cilt.62, sa.8, 2026 (SCI-Expanded, Scopus)

2. Clinical and geriatric factors associated with fracture risk in older adults with bone metastases: A prospective observational study

Güner İ., AKIN S., YALÇIN N.

Supportive Care in Cancer , cilt.34, sa.6, 2026 (SCI-Expanded, Scopus)

3. Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort—A Turkish Oncology Group (TOG) Study

Kidi M. M., Asoglu H., Soysal M., KÖŞECİ T., KARA İ. O., ŞAHİN B., et al.

Medicina (Lithuania) , cilt.62, sa.6, 2026 (SCI-Expanded, Scopus)

4. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint Inhibitors

Şahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.

Journal of Oncological Science , cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)

5. PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CT

Kaya G., AKIN S., BÜYÜKAŞIK Y., BOZKURT M. F., TUNCEL M., Kiratli P. O.

European Journal of Nuclear Medicine and Molecular Imaging , cilt.53, sa.4, ss.2325-2336, 2026 (SCI-Expanded, Scopus)

6. Cell therapy in sarcoma: Current landscape and future directions

Sahin T. K., Germetaki T., GÜVEN D. C., AKIN S., DİZDAR Ö., Thistlethwaite F., et al.

Journal for ImmunoTherapy of Cancer , cilt.14, sa.1, 2026 (SCI-Expanded, Scopus)

7. Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma

Sahin T. K., Gungor H. N., Gezmis E., Sahin E. A., BARIŞTA İ., AYHAN E. A., et al.

Expert Review of Hematology , cilt.19, sa.8, ss.967-973, 2026 (SCI-Expanded, Scopus)

8. Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study

ŞAHİN T. K., Sahin E. A., Gungor H. N., GÜVEN D. C., BARIŞTA İ., AKIN S.

CANCER MEDICINE , cilt.14, sa.7, 2025 (SCI-Expanded, Scopus)

9. The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas

YAZICI G., AKIN S., KAHVECİOĞLU A., YİĞİT E., TÜRKER F. A., YILDIZ F.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK , cilt.47, sa.3, ss.891-898, 2025 (SCI-Expanded, Scopus)

10. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer

BAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.5, 2025 (SCI-Expanded, Scopus)

11. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases

KERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.

CANCER CONTROL , cilt.32, 2025 (SCI-Expanded, Scopus)

12. Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management

AKYILDIZ A., Ismayilov R., Rustamova N., Tokatli M., KOÇ İ., AKIN S., et al.

Annals of Hematology , cilt.103, sa.3, ss.905-915, 2024 (SCI-Expanded, Scopus)

13. Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation

Ucgul E., Guven D. C., Ucgul A. N., ÖZBAY Y., ONUR M. R., AKIN S.

CANCER CONTROL , cilt.31, 2024 (SCI-Expanded, Scopus)

14. Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report

KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.

PLASMATOLOGY , cilt.18, 2024 (ESCI, Scopus)

15. Bilgisayarlı Tomografi, Pozitron Emisyon Tomografisi ve Nükleer Manyetik Rezonans Görüntülemede Temel Kavram ve İlkeler.

BAYARI S. H., AKIN S., TUNCEL M.

Batı Karadeniz Tıp Degisi , cilt.7, sa.3, ss.269-278, 2023 (TRDizin)

16. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future

Srour S. A., AKIN S.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.1, ss.19-30, 2023 (Scopus)

17. A Novel Tumor Marker for Anaplastic Lymphoma Kinase (+) Lymphoma: Beta-Human Chorionic Gonadotropin

Moral K., SEYHAN E., KUTLAY D. Y., AKIN S.

Journal of Oncological Science , cilt.9, sa.1, ss.46-49, 2023 (Scopus, TRDizin)

18. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , cilt.15, sa.4, ss.307-310, 2022 (ESCI, Scopus)

19. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , cilt.27, sa.11, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , cilt.27, 2022 (SCI-Expanded, Scopus)

21. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

Akin S., Hosing C., Khouri I., Ahmed S., Alousi A., Fowler N., et al.

BLOOD ADVANCES , cilt.6, sa.7, ss.2267-2274, 2022 (SCI-Expanded, Scopus)

22. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement

Kupik O., Akin S., Tuncel M., Eren G., Türker A., Kars A., et al.

NUCLEAR MEDICINE COMMUNICATIONS , cilt.41, sa.6, ss.540-549, 2020 (SCI-Expanded, Scopus)

23. Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx ) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience

Acar R., Erturk I., Kiziloz H., Okcelik S., Yildiz B., Aykan M. B., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.30, sa.4, ss.191-196, 2020 (SCI-Expanded, Scopus, TRDizin)

24. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.

JOURNAL OF BUON , cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded, Scopus)

25. Association between androgen receptor status and prognosis in triple negative breast cancer

Sunar V., Dogan H. T., Sarici F., ATEŞ Ö., AKIN S., BAŞPINAR B., et al.

JOURNAL OF BUON , cilt.23, sa.5, ss.1325-1330, 2018 (SCI-Expanded, Scopus)

26. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma

AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.

CURRENT PROBLEMS IN CANCER , cilt.42, sa.3, ss.344-349, 2018 (SCI-Expanded, Scopus)

27. Farklı Trombositopeni Sebeplerinin Klinik ve Laboratuvar Bulguları

AKIN S., AKIN Ş., Karaağaç A. T., HAZNEDAROĞLU İ. C.

Journal of Contemporary Medicine , cilt.7, sa.4, ss.316-322, 2017 (Hakemli Dergi)

28. Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms

AKIN S., DİZDAR Ö., Hayran M.

ANNALS OF SURGICAL ONCOLOGY , cilt.24, 2017 (SCI-Expanded, Scopus)

29. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database

DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.

JOURNAL OF BUON , cilt.22, sa.2, ss.530-534, 2017 (SCI-Expanded, Scopus)

30. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma

Akin S., Aksoy D. Y., AKIN S., KILIÇ M., Yetisir F., BAYRAKTAR M.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.47, sa.6, ss.1723-1727, 2017 (SCI-Expanded, Scopus, TRDizin)

31. Symptomatic Adrenal Insufficiency due to Bilateral Adrenal Non-Hodgkin’s Lymphoma

AKIN Ş., Akın S., TUNCEL M., ERSÖZ G. N.

Turkish Journal of Endocrinology and Metabolism , cilt.20, ss.108-110, 2016 (Scopus, TRDizin)

32. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience

Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.

JOURNAL OF BUON , cilt.21, sa.4, ss.826-831, 2016 (SCI-Expanded, Scopus)

33. Interpretation of survival data: which graphical analysis is appropriate?

Dizdar O., AKIN S., HAYRAN M.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , cilt.8, sa.4, ss.312, 2016 (SCI-Expanded, Scopus)

34. Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R., AKIN S., et al.

JOURNAL OF BUON , cilt.21, sa.4, ss.799-808, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

35. Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer

Karatas F., Sahin S., Erdem G. U., ATEŞ Ö., BABACAN T., AKIN S., et al.

JOURNAL OF BUON , cilt.21, sa.4, ss.851-858, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

36. Analysis of the Adjuvant Hormone Therapy Randomized Trial

Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.34, sa.17, ss.2070-2071, 2016 (SCI-Expanded, Scopus)

37. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.

JOURNAL OF BUON , cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. Leg cramps associated with tamoxifen use - possible mechanism and treatment recommendations

Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R., Altundag K.

JOURNAL OF BUON , cilt.21, sa.2, ss.520, 2016 (SCI-Expanded, Scopus)

39. Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy

AKIN S., DİZDAR Ö., ÖZIŞIK L., TANRIOVER M., KAMISLI S., ERMAN M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.3, ss.167-172, 2016 (SCI-Expanded, Scopus, TRDizin)

40. Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer

Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R., Altundag K.

JOURNAL OF BUON , cilt.20, sa.6, ss.1640, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Does eribulin mesylate cause recurrent transient diplopia?

Karatas F., Hacioglu B., AKIN S., BABACAN T., SEVER A. R., Altundag K.

JOURNAL OF BUON , cilt.20, sa.5, ss.1379, 2015 (SCI-Expanded, Scopus)

42. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.

TUMORI J , cilt.101, sa.4, ss.418-423, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. Can aromatase inhibitors cause forgetfulness in women with breast cancer ?

Karatas F., AKIN S., BABACAN T., SEVER A. R., Altundag K.

JOURNAL OF BUON , cilt.20, sa.3, ss.935, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

44. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis

BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.

JOURNAL OF BUON , cilt.20, sa.2, ss.479-486, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

45. Comparison of three different induction regimens for nasopharyngeal cancer

KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., et al.

Asian Pacific Journal of Cancer Prevention , cilt.16, sa.1, ss.59-63, 2015 (SCI-Expanded, Scopus)

46. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab

ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.

JOURNAL OF BUON , cilt.20, sa.1, ss.349, 2015 (SCI-Expanded, Scopus)

47. Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats

KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., et al.

Anticancer Research , 2015 (SCI-Expanded, Scopus)

48. How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?

Hacioglu B., AKIN S., BABACAN T., SEVER A. R., Altundag K.

FUTURE ONCOLOGY , cilt.11, sa.20, ss.2799-2801, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

49. Clinical implications of intratumoral heterogeneity ofHER2gene amplification in locally advanced HER2-positive breast cancer patients

Hacioglu B., AKIN S., SEVER A. R., Altundag K.

FUTURE ONCOLOGY , cilt.11, sa.18, ss.2495-2497, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

50. Molecular subtypes in patients with inflammatory breast cancer; A single center experience

KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

51. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia

GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.

JOURNAL OF BUON , cilt.19, sa.4, ss.1127, 2014 (SCI-Expanded, Scopus)

52. Breast sarcoma: A rare malignancy

Gul G., BABACAN T., AKIN S., Sarici F., Altundag K.

JOURNAL OF BUON , cilt.19, sa.2, ss.577, 2014 (SCI-Expanded, Scopus)

53. A novel targeted therapy in breast cancer: Cyclin dependent kinase inhibitors

AKIN S., BABACAN T., Sarici F., Altundag K.

JOURNAL OF BUON , cilt.19, sa.1, ss.42-46, 2014 (SCI-Expanded, Scopus)

54. Nasopharyngeal sarcoidosis: a rare involvement

Akin S., Akin S., KARADAĞ Ö., KALYONCU U., Balci S., ÖZGEN MOCAN B.

RHEUMATOLOGY INTERNATIONAL , cilt.32, sa.5, ss.1407-1409, 2012 (SCI-Expanded, Scopus)

55. Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature

Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., et al.

MEDICAL ONCOLOGY , cilt.27, sa.1, ss.55-58, 2010 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 12

1. Kemoterapi Tedavisi Gören Kanser Hastalarında Fiziksel Aktivite ile Sağlık Okuryazarlığı, Yaşam Kalitesi ve Sosyal Destek Algısı Arasındaki İlişkinin Araştırılması

Karakaş O., İmece A. M., KUMBAROĞLU F. B., AKIN S., ATASAVUN UYSAL S.

19. ULUSLARARASI FİZYOTERAPİDE GELİŞMELER KONGRESİ, Ankara, Türkiye, 09 Nisan 2025, (Özet Bildiri)

2. The Role of FDG PET/CT Detecting Bone Marrow Involvement in Non-Hodgkin's Lymphoma Patients

KUPIK O., Akin S., TUNCEL M., TÜRKER A., Kars A., Erbas B.

31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Düsseldorf, Almanya, 13 - 17 Ekim 2018, cilt.45, (Özet Bildiri)

3. The impact of the total size of lesions in multifocal multicentric breast cancer on survival

Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

4. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma

ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)

5. The impact of the total size of lesions in multifocal/multicentric breast cancer on survival.

Karakas Y., Dizdar O., Akin S., Ates O., Sendur M. A. N., Aksoy S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

6. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.

ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

7. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.

Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

8. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.

Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.

9. Signet ring cell carcinoma of breast: Single center experience.

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.

10. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)

11. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

12. Is there any correlation between molecular subtypes and blood groups in breast cancer?

Kucukoztas N., Oguz A., Babacan T., Dizdar O., Rahatli S., Sarici S. F., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

118

H-İndeks (WoS)

Atıf (Scopus)

172

H-İndeks (Scopus)

Proje

Tez Danışmanlığı

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler